Joint structure modification in osteoarthritis: Development of SMOAD drugs

Current Rheumatology Reports

Volumn 3, Issue 6, 2001, Pages 506-512

  Beary, John F ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Diacerein; Joint Space Width; Medial Tibial Plateau; Osteoarthritis; Subchondral Bone

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTICULAR CARTILAGE; DRUG EFFECT; HIP; HIP OSTEOARTHRITIS; HUMAN; KNEE; KNEE OSTEOARTHRITIS; REVIEW;

ANTIRHEUMATIC AGENTS; CARTILAGE, ARTICULAR; HIP JOINT; HUMANS; KNEE JOINT; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE;

EID: 0035651005     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-001-0065-7     Document Type: Article

References (43)

1. Lawrence RC, Helmick CG, Arnett FC, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778–799. DOI: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V
2. Osteoarthritic Disorders. Edited by Keuttner KE, Goldberg V. Rosemont, IL: American Academy of Orthopedic Surgeons; 1995:xxi-xxv.
3. Bullough PG: Pathology of osteoarthritis. In Rheumatology. Edited by Klippel JH, Dieppe PA. Philadelphia: Mosby; 1998:8.1–8.8.
4. Felson DT: The verdict favors nonsteroidal anti-inflammatory drugs for treatment of osteoarthritis, and a plea for more evidence on other treatments. Arthritis Rheum 2001, 44:1477–1480. Advice on how to assess the quality of clinical trials in osteoarthritis, particularly those coming from the nutriceutical or herbal medicine sectors that are not regulated by the FDA. DOI: 10.1002/1529-0131(200107)44:7<1477::AID-ART267>3.0.CO;2-O
5. Bellamy N: Clinical trials design: structure modifying agents for osteoarthritis. Future guidelines: areas for development. Osteoarthritis Cartilage 1999, 7:424–426. Perspective from one of the creators of the WOMAC instrument. A useful reference list that lists key expert consensus conferences such as OMERACT III of 1996 and OARSI 1996. DOI: 10.1053/joca.1998.0232
6. Hammad TA: Structure modification in knee osteoarthritis: methodology and outcome parameters. Osteoarthritis Cartilage 2001, 9:488–498. DOI: 10.1053/joca.2001.0416
7. US Food and Drug Administration: Guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). Rockville, MD: US FDA Center for Drug Evaluation and Research. www.fda.gov/cder/guidance/clinical. February 1998.
8. Committee for Proprietary Medicinal Products: Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis. London, UK: European Medicines Evaluation Agency (EMEA). Available on the web at www.emea.eu. July 23, 1998.
9. Bellamy N, Kirwan J, Boers M, et al.: Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997, 24:799–802.
10. Group for the Respect of Ethics and Excellence in Science (GREES): Osteoarthritis Section. Recommendations for the registration of drugs used in the treatment of Osteoarthritis. Ann Rheum Dis 1996, 55:552–557.
11. Altman R, Brandt K, Hochberg M, et al.: Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996, 4:217–243. DOI: 10.1016/S1063-4584(05)80101-3
12. Bellamy N: WOMAC Osteoarthritis Index-User’s Guide version 3.0, 1998. Brisbane, Australia: University of Queensland; 1998. A validated instrument to measure the pain and function domains in knee and hip OA.
13. Lequesne M: Indices of severity and disease activity for Osteoarthritis. Semin Arthritis Rheum 1991, 20:48–54. DOI: 10.1016/0049-0172(91)90027-W
14. Buckland-Wright JC, Macfarlane DG, Lynch JA, et al.: Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation. Ann Rheum Dis 1995, 54:263–268.
15. Buckland-Wright JC, Wolfe F, Ward RJ, et al.: Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy of standing extended, semiflexed (MTP), and schuss views. J Rheumatol 1999, 26:2664–2674. The relative performance and variability of various radiograph methods is provided in the paper and in references to earlier work by the same author who has played a major role in creating and validating modern radioanatomic methods for clinical trial assessment of osteoarthritis. One can rate the performance of standard x-ray, microfocal x-ray, various knee positions, and the value of adjunctive fluoroscopic positioning of the knee for longitudinal studies.
16. Mazzuca SA, Brandt KD, Dieppe PA, et al.: Effect of alignment of the medial tibial plateau and x-ray beam on apparent progression of osteoarthritis in the standing anteroposterior knee radiograph. Arthritis Rheum 2001, 44:1786–1794. The importance of medial tibial plateau alignment with the central x-ray beam is emphasized, if one is to measure changes in knee joint space width over time. Only 14% of serial longitudinal x-rays showed alignment of the medial tibial plateaus in both images. It is concluded that the standard clinical standing extended knee view is unsatisfactory for clinical trial SMOAD purposes, or for accurately determining the rate at which joint space is lost as knee OA progresses. DOI: 10.1002/1529-0131(200108)44:8<1786::AID-ART315>3.0.CO;2-L
17. Peterfy CG: Magnetic resonance imaging. In Osteoarthritis. Edited by Brandt KD, Doherty M, Lohmander SL. New York: Oxford University Press; 1998:473–494. Clinical investigators can expect that MRI will steadily progress and become suitable for proof of concept studies in OA as some of the issues with assessing data on joint space width and longitudinal change in cartilage volumes are successfully dealt with. This chapter appears in a 598 page authoritative book devoted to osteoarthritis that covers many topics relevant to planning and conducting clinical trials in OA.
18. National Institutes of Health: Public-Private Partnership Osteoarthritis Initiative; Bethesda MD. www.niams.nih.gov. July 17, 2001.
19. Greenwald RA, Zucker S, Golub LM: Inhibition of matrix metalloproteinases: therapeutic applications. NY: NY Academy of Sciences; 1999. An excellent book of informative preclinical and clinical papers on MMP-based therapeutics.
20. Altman RD, Moskowitz R, and the Hyalgan Study Group: Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol 1998, 25:2203–2212.
21. Brandt KD, Smith GN, Simon LS: Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 2000, 43:1192–1203. DOI: 10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L
22. Pelletier JP, Yaron M, Haraoui B, et al., and the diacerein study group. Efficacy and safety of diacerein in osteoarthritis of the knee. Arthritis Rheum 2000, 43:2339–2348. DOI: 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P
23. Reginster JY, Deroisy R, Rovati LC, et al.: Long term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001, 357:251–256. This study used the standing extended view of the knee, which is too variable for longitudinal studies. DOI: 10.1016/S0140-6736(00)03610-2
24. National Institutes of Health: NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Bethesda, MD. www.niams.nih.gov. 2000. The GAIT study will recruit 1588 patients who will be randomized to one of five study arms: glucosamine (derived from crab shells), chondroitin (from cattle trachea), glucosamine plus chondroitin, celecoxib as active control, and placebo. The primary endpoint is symptoms and function change at 6 months. Half of the patients will be in an extended structure study using a 6∮ knee flexion x-ray, for a total of 2 years of study time.
25. Towheed TE, Anastassiades TP: Glucosamine therapy for osteoarthritis. J Rheumatol 1999, 26:2294–2297. Examines some of the biochemistry, pharmacokinetic, and experimental design issues that need to be addressed in glucosamine OA research.
26. Bigg HF, Rowan AD: The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Curr Opin Pharmacol 2001, 1:314–320. Penetrating and well-referenced state-of-the-art commentary on MMP as a therapeutic target in OA and RA with updates on several molecules that have been or are likely to be studied in humans. DOI: 10.1016/S1471-4892(01)00055-8
27. Harris ED, Evanson JM, DiBona DR, Krane SM: Collagenase and rheumatoid arthritis. Arthritis Rheum 1970, 13:83–94. DOI: 10.1002/art.1780130109
28. Yu LP, Smith GN, Brandt KD, et al.: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992, 35:1150–1159. DOI: 10.1002/art.1780351007
29. Robinson DR: Inflammation. In Rheumatology. Edited by Klippel JH, Dieppe PA. Philadelphia: Mosby; 1998:1–7.1.
30. Cawston TE: Tissue destruction and repair. In Rheumatology. Edited by Klippel JH, Dieppe PA. Philadelphia: Mosby; 1998:7.1–8.6.
31. Kelley WN, Harris ED, Ruddy S, Sledge CB: Immune and inflammatory responses. In Textbook of Rheumatology. Philadelphia: WB Saunders; 1997:95–342.
32. Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis an inflammatory disease: potential implications for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237–1247. A review that puts joint inflammation in OA into context with joint organ tissue degeneration/repair activities. The paper concludes with a commentary on futuristic OA therapies such as chondrocyte anti-apoptosis and gene therapy. DOI: 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F
33. Radin EL, Rose RM: Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986, 213:34–39.
34. Ding M, Odgaard A, Danielsen CC, Hvid I: Deterioration in the quality of tibial cancellous bone in early stage human osteoarthrosis. Abstract #0300. Ortho Res Soc 2001, 26:300.
35. Bullough PG: The geometry of diarthrodial joints, its physiologic maintenance, and the possible significance of age-related changes in geometry-to-load distribution and the development of osteoarthritis. Clin Orthop 1981, 156:61–66.
36. Radin EL, Paul IL, Lowy M: A comparison of the dynamic force transmitting properties of subchondral bone and articular cartilage. J Bone Joint Surg 1970, 52:444–456.
37. Hoshino A, Wallace WA: Impact absorbing properties of the human knee. J Bone Joint Surg 1987, 69:807–811.
38. Zysset PK, Sonny M, Hayes WC: Morphology-mechanical property relations in trabecular bone of the osteoarthritic proximal tibia. J Arthroplasty 1994, 9:203–216. DOI: 10.1016/0883-5403(94)90070-1
39. Westacott CI, Webb GR, Warnock MG, Sims JV, Elson CJ:Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum 1997, 40:1282–1291.
40. Mundy GR: Bone remodeling. In Primer on the Metabolic Bone Diseases, edn 4. Philadelphia: Lippincott Williams & Wilkins; 1999:30–38. This book is published by the American Society for Bone and Mineral Research and is updated regularly. Chapters 1 through 5 provide an excellent overview of bone microanatomy and ultrastructure, molecular and cellular biology of bone, bone growth and remodeling, and bone biomechanics.
41. Felson DT, Chaisson CE, Hill CL, et al.: The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001, 134:541–549. Important data from MRI images and associated WOMAC algofunctional data in 401 patients that will prompt clinical investigators to look further at the role that subchondral bone plays in knee OA.
42. McAlindon TE, Watt I, McCrae FM, Goddard P, Dieppe PA:Magnetic resonance imaging in osteoarthritis of the knee: correlation with radiographic and scintigraphic findings. Ann Rheum Dis 1991, 50:14–19. This and the following paper from the same group provided early evidence that imaging methods could document disease activity in subchondral bone, and in the case of bone scintigraphy, be used to predict disease progression. DOI: 10.1136/ard.50.1.14
43. Dieppe PA, Cushnaghan J, Young P, Kirwan J: Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993, 52:557–563.